Klaria Pharma Holding AB (publ.) (FRA:6FN)

Germany flag Germany · Delayed Price · Currency is EUR
0.0648
-0.0016 (-2.41%)
Feb 20, 2026, 4:00 PM EST
Market Cap17.51M +36.3%
Revenue (ttm)831.53K +300.3%
Net Income-3.59M
EPS-0.02
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume3,169
Average Volume20
Open0.0648
Previous Close0.0664
Day's Range0.0648 - 0.0648
52-Week Range0.0308 - 0.1470
Betan/a
RSI40.65
Earnings DateFeb 20, 2026

About FRA:6FN

Klaria Pharma Holding AB (publ.), a pharmaceutical company develops and commercializes medication for migraine and cancer related pain, and opioid overdose and anaphylactic shock. Its product pipeline includes Sumatriptan, a novel the treatment of migraine which is in final stage of approval; Epinephrine/Adrenaline which is in Phase I clinical trial for the treatment of acute allergic reaction; and Sirolimus which is in pre-clinical stage for prevention of organ transplant rejection. The company is also involved in commercialization and sale of... [Read more]

Industry Pharmaceutical Preparations
Founded 2014
Employees 4
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 6FN
Full Company Profile

Financial Performance

In 2025, FRA:6FN's revenue was 9.00 million, an increase of 300.31% compared to the previous year's 2.25 million. Losses were -38.89 million, -18.56% less than in 2024.

Financial numbers in SEK Financial Statements